Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Mechanisms of Retrovirus-induced Cancers

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PIWIs, piRNAs and Retrotransposons: Complex battles during reprogramming in gametes and early embryos.

Reproduction in domestic animals = Zuchthygiene·2017

Same author

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Blood cancer journal·2017

Same author

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Leukemia·2017

Same author

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Leukemia·2017

Same author

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Blood cancer journal·2017

Same author

Natural history of t(11;14) multiple myeloma.

Leukemia·2017

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Measles virus as an oncolytic vector platform.

B Blechacz¹, S J Russell

¹Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Blechacz.Boris@mayo.edu

Current Gene Therapy

|June 10, 2008

Summary

Measles virus, a safe vaccine strain, shows promise for cancer gene therapy due to its tumor-targeting ability. Genetic engineering enhances its potential for oncolytic virotherapy against cancer.

Area of Science:

Oncolytic virotherapy
Cancer gene therapy
Viral vector systems

Background:

Viral vectors are crucial for genetic disease therapies.
Oncolytic viruses offer significant potential for cancer treatment.
An ideal viral vector selectively targets and eliminates cancer cells while sparing healthy tissues.

Purpose of the Study:

To review measles virus as an anticancer agent.
To explore its application in oncolytic virotherapy.
To discuss advancements in measles virus targeting and immune evasion strategies.

Main Methods:

Utilizing the Edmonston vaccine strain of measles virus for its tumor selectivity and oncolytic properties.
Employing genetic engineering to insert therapeutic transgenes and retarget measles virus.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Experiment Videos

Last Updated: Jul 4, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Developing immune-evasive strategies to enhance viral gene therapy efficacy.

Main Results:

Measles virus demonstrates tumor selectivity and oncolysis.
Recombinant measles viruses allow for non-invasive monitoring of viral replication and spread.
Engineered measles virus exhibits enhanced efficacy through immune evasion.

Conclusions:

Measles virus is an optimal platform for oncolytic virotherapy due to its safety and tumor-targeting capabilities.
Genetic modifications and immune evasion strategies significantly improve measles virus-based cancer therapies.
Further development holds promise for effective measles virus-driven cancer treatment.